Long-term safety study of Lunsekimig for asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests the long-term safety and effectiveness of Lunsekimig, an investigational drug, for adults with asthma. It is for people who have already completed a previous Lunsekimig study and are on stable asthma medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the full treatment period in a previous Lunsekimig study (DRI16762 or ACT18301).
- You are on a stable daily dose of medium to high-dose inhaled corticosteroids plus other controller medicines as specified in your previous study.
- You are willing to follow study procedures and attend all visits for this long-term extension trial.
- You agree to use effective birth control during the study and for 8 weeks after the last dose, if applicable.
- You have not developed any new medical condition or allergy that would make participation unsafe, in the investigator's opinion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called tilrekimig for people with severe asthma that isn't well controlled with current treatments. It aims to see if tilrekimig can reduce asthma attacks and improve breathing.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study is testing an investigational medication for people with uncontrolled asthma. Participants must have moderate-to-severe asthma, be on appropriate maintenance therapy, and meet specific safety criteria.
This study is testing whether an investigational drug called GSK5784283 can improve asthma control compared to a placebo. It is for people with uncontrolled asthma who are already on standard daily asthma medications.
This trial tests a new inhaled medication called LQ036 to see if it can help people whose asthma is not well controlled with their current inhalers. Participants must have had at least one severe asthma flare-up in the last year and show signs of airway inflammation.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.